Lixte Biotechnology Holdings Inc (LIXT)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Lixte Biotechnology Holdings Inc chart...

About the Company

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in

Exchange

NASDAQ

Website

lixte.com

$1M

Total Revenue

5

Employees

$9M

Market Capitalization

-2.41

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LIXT News

Why Lixte Biotechnology Stock Is Soaring

on MSN ago, source:

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the ...

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

2d ago, source:

LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE ...

Biotech Steals The Show Following Pre-Clinical Data Announcement

1d ago, source: All Penny Stocks (English) on MSN

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, ...

Lixte Biotechnology gets grant for in vivo delivery of endothall to cancer cells

23h ago, source: Pharmaceutical Technology

Discover a groundbreaking patent by Lixte Biotechnology for in vivo delivery of endothall to cancer cells, focusing on brain cancer treatment. Explore new possibilities in cancer therapy today!

Lixte Biotechnology Holdings, Inc.

5mon ago, source: CNN

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also ...

Lixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer Treatment

1d ago, source:

By Chris Wack Lixte Biotechnology Holdings shares were up 51% at $3.41 after the company said pre-clinical data showed that its lead clinical ...

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

7d ago, source:

Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) ...

LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q4 2023

9d ago, source: Business Insider

The post LIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q4 2023 appeared first on InvestorPlace. Lixte Biotechnology Holdings NewsMORE Related Stocks Indices Commodities Currencies ...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.22%

on MSN ago, source:

U.S. stocks were higher after the close on Wednesday, as gains in the Utilities, Basic Materials and Telecoms sectors led ...

Gold Moves Higher; Velo3D Shares Plummet

on MSN ago, source:

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74 ...

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

on MSN ago, source:

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary ...

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

3d ago, source:

Another one of the Street’s favorite biotech stocks is Immunovant (NASDAQ: IMVT ), where recent weakness is an opportunity.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...